Literature DB >> 25561876

Alzheimer's disease and type 2 diabetes via chronic inflammatory mechanisms.

Gohar Mushtaq1, Jalaluddin A Khan1, Taha A Kumosani2, Mohammad A Kamal3.   

Abstract

Recent evidence has indicated that type 2 diabetes mellitus (T2DM) increases the risk of developing Alzheimer's disease (AD). Therefore, it is crucial to investigate the potential common processes that could explain this relation between AD and T2DM. In the recent decades, an abundance of evidence has emerged demonstrating that chronic inflammatory processes may be the major factors contributing to the development and progression of T2DM and AD. In this article, we have discussed the molecular underpinnings of inflammatory process that contribute to the pathogenesis of T2DM and AD and how they are linked to these two diseases. In depth understanding of the inflammatory mechanisms through which AD and T2DM are associated to each other may help the researchers to develop novel and more effective strategies to treat together AD and T2DM. Several treatment options have been identified which spurn the inflammatory processes and discourage the production of inflammatory mediators, thereby preventing or slowing down the onset of T2DM and AD.

Entities:  

Keywords:  Alzheimer’s disease; Anti-inflammatory drugs; C-reactive protein; Cytokines; Hyperinsulinemia; Inflammation; Oxidative stress; Transgenic mouse models; Tumor necrosis factor-α; Type 2 diabetes mellitus; β-Amyloid

Year:  2014        PMID: 25561876      PMCID: PMC4281591          DOI: 10.1016/j.sjbs.2014.05.003

Source DB:  PubMed          Journal:  Saudi J Biol Sci        ISSN: 1319-562X            Impact factor:   4.219


  102 in total

1.  Inflammation.

Authors:  J B Cone
Journal:  Am J Surg       Date:  2001-12       Impact factor: 2.565

Review 2.  Current view from Alzheimer disease to type 2 diabetes mellitus.

Authors:  Mahmood Rasool; Arif Malik; Aamer M Qazi; Ishfaq A Sheikh; Abdul Manan; Sumaira Shaheen; Mahmood H Qazi; Adeel G Chaudhary; Adel M Abuzenadah; Muhammad Asif; Mohammed H Alqahtani; Zafar Iqbal; Munvar M Shaik; Siew H Gan; Mohammad A Kamal
Journal:  CNS Neurol Disord Drug Targets       Date:  2014-04       Impact factor: 4.388

Review 3.  Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes.

Authors:  Joseph L Evans; Ira D Goldfine; Betty A Maddux; Gerold M Grodsky
Journal:  Endocr Rev       Date:  2002-10       Impact factor: 19.871

Review 4.  Glial-neuronal interactions in Alzheimer's disease: the potential role of a 'cytokine cycle' in disease progression.

Authors:  W S Griffin; J G Sheng; M C Royston; S M Gentleman; J E McKenzie; D I Graham; G W Roberts; R E Mrak
Journal:  Brain Pathol       Date:  1998-01       Impact factor: 6.508

5.  A high plasma concentration of TNF-alpha is associated with dementia in centenarians.

Authors:  H Bruunsgaard; K Andersen-Ranberg; B Jeune; A N Pedersen; P Skinhøj; B K Pedersen
Journal:  J Gerontol A Biol Sci Med Sci       Date:  1999-07       Impact factor: 6.053

Review 6.  Molecular mechanisms linking diabetes mellitus and Alzheimer disease: beta-amyloid peptide, insulin signaling, and neuronal function.

Authors:  Shuko Takeda; Naoyuki Sato; Hiromi Rakugi; Ryuichi Morishita
Journal:  Mol Biosyst       Date:  2011-03-24

7.  Tumor necrosis factor-alpha suppresses insulin-induced tyrosine phosphorylation of insulin receptor and its substrates.

Authors:  R Feinstein; H Kanety; M Z Papa; B Lunenfeld; A Karasik
Journal:  J Biol Chem       Date:  1993-12-15       Impact factor: 5.157

8.  Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance.

Authors:  G S Hotamisligil; N S Shargill; B M Spiegelman
Journal:  Science       Date:  1993-01-01       Impact factor: 47.728

9.  Elevated circulating tumor necrosis factor levels in Alzheimer's disease.

Authors:  H Fillit; W H Ding; L Buee; J Kalman; L Altstiel; B Lawlor; G Wolf-Klein
Journal:  Neurosci Lett       Date:  1991-08-19       Impact factor: 3.046

10.  Impact and Therapeutic Potential of PPARs in Alzheimer's Disease.

Authors:  Michael T Heneka; Elisabet Reyes-Irisarri; Michael Hüll; Markus P Kummer
Journal:  Curr Neuropharmacol       Date:  2011-12       Impact factor: 7.363

View more
  21 in total

Review 1.  Status of acetylcholinesterase and butyrylcholinesterase in Alzheimer's disease and type 2 diabetes mellitus.

Authors:  Gohar Mushtaq; Nigel H Greig; Jalaluddin A Khan; Mohammad A Kamal
Journal:  CNS Neurol Disord Drug Targets       Date:  2014       Impact factor: 4.388

Review 2.  Current Update on Synopsis of miRNA Dysregulation in Neurological Disorders.

Authors:  Mohammad A Kamal; Gohar Mushtaq; Nigel H Greig
Journal:  CNS Neurol Disord Drug Targets       Date:  2015       Impact factor: 4.388

3.  Biochemical Analysis and Association of Butyrylcholinesterase SNPs rs3495 and rs1803274 with Substance Abuse Disorder.

Authors:  Sadaf Munir; Rabia Habib; Sliha Awan; Nazia Bibi; Arooj Tanveer; Sajida Batool; Syed M Nurulain
Journal:  J Mol Neurosci       Date:  2019-02-01       Impact factor: 3.444

4.  Kinetics and Molecular Docking Study of an Anti-diabetic Drug Glimepiride as Acetylcholinesterase Inhibitor: Implication for Alzheimer's Disease-Diabetes Dual Therapy.

Authors:  Syed Mohd Danish Rizvi; Sibhghatulla Shaikh; Deeba Naaz; Shazi Shakil; Adnan Ahmad; Mohd Haneef; Adel M Abuzenadah
Journal:  Neurochem Res       Date:  2016-02-17       Impact factor: 3.996

Review 5.  Neuroprotective Mechanisms Mediated by CDK5 Inhibition.

Authors:  Gohar Mushtaq; Nigel H Greig; Firoz Anwar; Fahad A Al-Abbasi; Mazin A Zamzami; Hasan A Al-Talhi; Mohammad A Kamal
Journal:  Curr Pharm Des       Date:  2016       Impact factor: 3.116

6.  Telomere Shortening in the Alzheimer's Disease Neuroimaging Initiative Cohort.

Authors:  Kelly N H Nudelman; Jue Lin; Kathleen A Lane; Kwangsik Nho; Sungeun Kim; Kelley M Faber; Shannon L Risacher; Tatiana M Foroud; Sujuan Gao; Justin W Davis; Michael W Weiner; Andrew J Saykin
Journal:  J Alzheimers Dis       Date:  2019       Impact factor: 4.472

7.  Letter to the editor regarding: Summary of the evidence on modifiable risk factors for cognitive decline and dementia: A population-based perspective.

Authors:  Angela R Kamer; Malvin N Janal; Mony de Leon
Journal:  Alzheimers Dement (Amst)       Date:  2015-09-02

8.  Assessment of common infections and incident dementia using UK primary and secondary care data: a historical cohort study.

Authors:  Rutendo Muzambi; Krishnan Bhaskaran; Liam Smeeth; Carol Brayne; Nish Chaturvedi; Charlotte Warren-Gash
Journal:  Lancet Healthy Longev       Date:  2021-07

Review 9.  Pathobiology of tobacco smoking and neurovascular disorders: untied strings and alternative products.

Authors:  Pooja Naik; Luca Cucullo
Journal:  Fluids Barriers CNS       Date:  2015-10-31

10.  Increased Subsequent Risk of Peptic Ulcer Diseases in Patients With Bipolar Disorders.

Authors:  Yi-Chao Hsu; Chih-Chao Hsu; Kuang-Hsi Chang; Chang-Yin Lee; Lee-Won Chong; Yu-Chiao Wang; Chia-Hung Kao
Journal:  Medicine (Baltimore)       Date:  2015-07       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.